Detecting disease earlier is only half the answer.

Oculomics-enhanced early detection!

About Ascento-CDA

The Challenge

Two gaps are failing patients — and clinicians

In dementia and diabetes — particularly in the senior population — the clinical system faces a dual failure: diseases are caught too late, and even when detected, clinicians lack the biological context needed to guide meaningful intervention.

Gap 1 — Diagnosis comes late

By the time dementia and diabetes are clinically visible, they have often progressed for 5–10 years. In seniors, overlapping conditions make this even harder to catch — and by then, treatment options are limited.

Gap 2 — No root-cause analysis

Standard screening confirms that disease is present — but not why. Without understanding the underlying biological drivers, clinicians cannot tailor interventions, predict progression, or confidently guide remediation.

The Consequence

A burden on patients, providers, and payers alike

Without early detection and root-cause clarity, the entire system bears the cost.

For health providers

No tools to detect or intervene before symptoms appear
Diagnosis without biological context — limiting treatment precision
Reactive care cycles with poor long-term outcomes
Growing pressure to perform under value-based care models

For insurers

High late-stage treatment costs that are largely preventable
Costly hospitalizations and emergency interventions
Poor performance on chronic disease quality metrics
Growing claims burden from an aging population

The Solution

IICM™ — detect earlier- remediate with precision.

The Inflammatory, Immunologic & Cognitive Mapping platform integrates three accessible, clinically validated data streams — then uses AI to map the specific biological drivers promoting disease in each patient, giving clinicians the context to act, not just diagnose.

Signal 01

OCT retinal imaging

Non-invasive eye scans revealing neurological and vascular changes associated with cognitive decline — detectable years before symptoms emerge.

Signal 02

Cytokine biomarker analysis

Blood-based mapping of inflammatory markers that expose the biological drivers of metabolic and cognitive disease at the cellular level.

Signal 03

Advanced cognitive testing

Structured assessments detecting subtle cognitive deficits that standard tests overlook — particularly in at-risk senior populations.

Opportunity

Advances in multi-modal data analysis — including Oculomics, the study of systemic disease through the eye — now make it possible to surface disease signals years earlier, and to identify the specific biological mechanisms promoting progression. For clinicians, this means earlier, more informed diagnostic decisions and targeted remediation. For insurers, a measurable path to reduced long-term costs.

WHAT'S NOW POSSIBLE — 1

Earlier detection to support confident diagnosis

By integrating OCT retinal imaging, cytokine biomarker analysis, and advanced cognitive testing, IICM™ surfaces biological signals years before they become clinically visible — giving doctors the data they need to identify at-risk patients and diagnose earlier and with greater certainty.

WHAT'S NOW POSSIBLE — 2

Root-cause intelligence for targeted remediation

Detection alone isn't enough. IICM™ maps the specific inflammatory and metabolic drivers promoting disease in each patient — giving clinicians the biological context to design interventions that address root cause, not just symptoms.

Value Proposition

For health providers & clinicians

Surface disease signals in at-risk patients years before symptoms appear
Enhance existing data streams with additional revenues behind each patient's trajectory
Build remediation plans grounded in root-cause evidence
Improve outcomes and performance under value-based care models

For insurers & payers

Improve financial performance
Incentivize providers with a clinically rigorous early detection tool
while providing better outcomes
Reduce high-cost late-stage interventions and hospitalizations
Improve chronic disease quality metrics across the network
Demonstrate measurable ROI on prevention programs

Medical Underpinnings

Disease-promoting drivers identified by IICM™

Beyond surfacing early signals, IICM™ maps which inflammatory and metabolic mechanisms are actively promoting progression — giving each clinician a patient-specific biological picture to inform diagnosis and guide remediation.

INFLAMMATORY

Cytokine dysregulation

Elevated pro-inflammatory cytokines (e.g. IL-6, TNF-α) accelerate neurodegeneration and insulin resistance. IICM™ identifies which are active — and informs which interventions can modulate them.

METABOLIC

Insulin resistance & glucose dysregulation

Chronic insulin resistance impairs brain glucose metabolism — a known precursor to both Type 2 diabetes and Alzheimer's-type dementia. Surfacing this driver early opens a concrete remediation window for clinicians to act on.